Successful liver allografts were established by combination with allogeneic bone marrow transplantation.
(BALB/c) and host (thymus)-type (C3H/HeN) liver tissue. Assays for both mixed-lymphocyte reaction and induction of cytotoxic T lymphocytes revealed that the newly developed T cells were tolerant of both donor (stem-cell)-type and host (thymus)-type major histocompatibility complex determinants.
We propose that liver allografts combined with bone marrow transplantation should be considered as a viable therapy for patients with liver disease such as liver cirrhosis and hepatoma.
Orthotopic liver transplantation in humans was first successful in 1963 (1) . Since then, more than 500 patients have been treated with this method (2, 3) . In all species, liver allografts are rejected less aggressively than allografts of other organs (4-6), probably because Ia antigens are less prominent on liver cells than on cells of other organs. In humans, however, aggressive destructive rejection of liver allografts usually occurs if an immunosuppressant is not employed. It would be useful if rejection could be controlled without giving immunosuppressive agents.
Fully allogeneic chimeras in mice accept the skin of both thymus-type and bone marrow-type (7) . In addition, allogeneic bone marrow transplantation permits effective treatment of autoimmune diseases in MRL/1 and BXSB mice without graft-versus-host reaction, provided that bone marrow cells from young nu/nu mice or T-cell-depleted marrow cells are used (8, 9) . Further, we have found that in these mice the newly developed T cells are tolerant ofboth bone marrow donor-type and host-type major histocompatibility complex (MHC) determinants (9) .
These data prompted us to examine the fate of liver allografts in radiation bone marrow chimeras in mice. Small animals have been of limited use as a model for liver transplantation because the surgery has been technically difficult. Mito et al. (10) discovered that, in rats, splenic pulp is a most suitable location for long-term survival of dispersed hepatocytes (10) .
In Cell Preparation. Spleens were removed aseptically, minced, and gently passed through a fine-mesh stainless-steel sieve into phosphate-buffered saline, as described previously (8) .
Mixed-Lymphocyte Reaction (MLR). Triplicate cultures were set up in 96-well round-bottom microwell trays (Coming, Corning, NY). Each well contained 2 x 105 responder cells and 105 stimulator cells in a total of 0.2 ml of RPMI 1640 medium supplemented with 2 mM L-glutamine, penicillin (100 units/ml), streptomycin (100 ,g/ml), 5% heat-inactivated human serum, and 50 ,M 2-mercaptoethanol (Wako, Osaka, Japan). Stimulator cells were treated with mitomycin C (50 ,ug/ml) for 30 min at 37°C. The cultures were incubated for 96 hr in a humidified 5% CO2 atmosphere.
[3H]Thymidine (0.5 kLCi; New England Nuclear, 1 Ci/mmol; 1 Ci = 37 GBq) was present during the last 4 hr of the culturing period. 3H incorporated into trichloroacetic acid-insoluble material was determined by liquid scintillation counting.
Abbreviations: MLR, mixed-lymphocyte reaction; CTL, cytotoxic T lymphocytes; MHC, major histocompatibility complex.
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Induction of Cytotoxic T Lymphocytes (CTL
Evidence for Induction of Tolerance. It is known that precursor T cells of donor bone marrow migrate into the host thymus and there differentiate into mature T cells. To ascertain whether or not newly developed T cells are tolerant of both host-type and donor-type MHC determinants, MLR and CTL assays were performed. The MLR assay showed that spleen cells of the chimeras respond significantly to the third-party cells, whereas they do not respond to MHC determinants of either bone marrow-donor type or host type (Fig. 2) . In accord with these results, the assay for induction of CTL showed that the T cells from C3H/HeN mice reconstituted with BALB/c nu/nu or BALB/c bone marrow cells, or with BALB/c fetal liver cells, are tolerant, in each model, of donor-type as well as host-type MHC determinants (Table 2) .
DISCUSSION
Liver allografts in every species studied have been reported to be rejected less aggressively than allografts of other organs (4 were irradiated and reconstituted with BALB/c nu/nu (H-2d) bone marrow cells, the C3H/HeN mice accepted liver tissue of either BALB/c bone marrow-donor type or C3H/HeN host (thymus) type, but rejected vigorously the third-party (C57BL/6J) liver tissue (Table 1) . Using assays for both MLR (Fig. 2) and CTL (Table 2) , we found that the newly developed T cells are tolerant of both donor-type and host-type MHC determinants. Slavin et al. (11) have also reported that irradiation bone marrow chimeras accept donor-type as well as host-type skin. Thus, it is likely that donor stem cells (or precursor T cells) migrate into the host thymus and there acquire self-tolerance of the recipient strain during differentiation in the thymus (12) .
Immunosuppressive agents, such as azathioprine, steroid hormones, antilymphocyte globulin, and, more recently, cyclosporine, have been used to prevent allograft rejection (13) . However, these agents exert cytotoxic effects on lymphocytes, especially T cells. Therefore, patients treated with these agents over long periods often suffer from lifethreatening infections, and many die of these infections. Cyclosporine has been impressively effective in prolonging kidney, heart, pancreas, and liver allograft survival in humans (2) as well as animals (14) . However, cyclosporine may produce serious damage to kidney and liver. In the present study, we showed that liver allografts coupled with simultaneous bone marrow or fetal liver transplantation produce no harmful side effects. We have previously reported that bone marrow transplantation can be used to treat and apparently cure autoimmune diseases in mice without inducing any graft-vs.-host reaction, provided that T cells and committed T-cell precursors have been entirely eliminated from the bone marrow (9) . Good et al. (15) , in summarizing extensive research with bone marrow transplants, have reported that more than 20 otherwise fatal human diseases can be treated by bone marrow transplantation from HLA-matched or -mismatched donors. This number of diseases now can be extended to at least 50 otherwise lethal diseases.
Based on these experiments, we think that liver allografts combined with bone marrow transplantation could become a viable therapy for many patients suffering from irreversible liver disease such as liver cirrhosis or liver cancer. Further, hematopoietic cells from fetal liver allografts conjoined with transplantation of fetal liver cells obtained from an aborted fetus might represent a valuable strategy that could be used to treat children with congenital liver diseases such as biliary atresia. Responder spleen cells (7.5 x 106) and mitomycin C (50 ,ug/ml)-treated stimulator cells (2.5 x 106)
were cocultured in RPMI 1640 medium containing 10% heat-inactivated human serum, supplemented with streptomycin (100 ,ug/ml), penicillin (100 units/ml), and 50 AiM 2-mercaptoethanol. After 4 days of coculture in a humidified 5% CO2 incubator, the cells were collected, and their cytotoxic activity was determined by 51Cr-release assay as described (9) . *Effector/target cell ratio. Medical Sciences: Nakamura et al.
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We also propose that consideration be given to the possibility that organ allografts of heart, kidney, or pancreas may be accomplished without a long-term immunosuppression if the organ transplantation is done simultaneously with allogeneic bone marrow transplantation from the same donor. Since recipients of such combined transplants would need to be treated only once, such a strategy could prove to be an advantage in managing patients for whom transplantation of organs or tissues must be undertaken.
